Sun Pharmaceutical Quarterly Results for Trading Insights
In Mar 2026, Sun Pharmaceutical (SUNPHARMA) reported revenue ₹15,018 Cr and net profit ₹2,710 Cr — revenue +11.8% YoY. Analyse Sun Pharmaceutical shareholding analysis to track promoter, FII and institutional holdings.
SUNPHARMA Quarterly Results — Revenue, Profit & EPS Highlights
Sun Pharmaceutical latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. View SUNPHARMA price range for the annual high/low range and current price position.
- Revenue of ₹15,018 Cr in Mar 2026 (-5.6% vs Jun 2026, +11.8% vs Mar 2025)
- Net Profit of ₹2,710 Cr in Mar 2026 (-6.6% vs Jun 2026, +25.8% vs Mar 2025)
- EBITDA of ₹4,361 Cr in Mar 2026 (-9.5% vs Jun 2026)
- Operating Margin of 27.0% in Mar 2026 (+0.0pp vs Jun 2026)
- Earnings Per Share of ₹11.30 in Mar 2026 (-6.6% vs Jun 2026)
Sun Pharmaceutical Quarterly Results — Revenue, EBITDA, Net Profit & EPS
SUNPHARMA quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Jun 2026 | Sept 2025 | Mar 2025 | Jun 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 15,018 | 15,907 | 14,875 | 13,429 | 14,251 | -5.6% | 11.8% |
| Net Profit (₹ Cr) | 2,710 | 2,901 | 3,125 | 2,154 | 2,293 | - | - |
| EBITDA (₹ Cr) | 4,361 | 4,821 | 4,924 | 3,824 | 3,883 | - | - |
| EPS (₹) | 11.30 | 12.10 | 13.00 | 9.00 | 9.50 | - | - |
| Operating Margin (%) | 27.0% | 27.0% | 31.0% | 25.0% | 25.0% | - | - |
SUNPHARMA Share Price Trend — 1-Year Movement Across Quarterly Results
Sun Pharmaceutical 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. For annual financials, live price and key ratios, visit Sun Pharmaceutical stock price NSE.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
SUNPHARMA vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Sun Pharmaceutical latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Divis Laboratories
Mar 2026 |
₹247,469.81 Cr | 9375.0 | 2,986 | 751 | -5.0% | - | 25.2% | 331.2 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹188,719.51 Cr | 4840.0 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 420.5 |
|
Zydus Life Science
Mar 2026 |
₹112,607.65 Cr | 1160.0 | 7,569 | 1,341 | -4.3% | - | 17.7% | 91.7 |
|
Cipla
Mar 2026 |
₹109,705.39 Cr | 1394.5 | 6,612 | 543 | -9.3% | - | 8.2% | 203.0 |
|
Laurus Labs
Mar 2026 |
₹103,852.21 Cr | 1954.0 | 1,823 | 282 | -10.5% | - | 15.5% | 377.9 |
All amounts in ₹ Crores